Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Identifying methods to slow disease progression in patients with HIV-1 infection remains a
top priority in many regions of the world. In many countries, medications known to slow
progression are not readily affordable or available. Many of the individuals living in these
countries are also co-infected with a variety of other diseases such as tuberculosis, malaria
and soil-transmitted helminths. There are data to suggest that infection with these agents
may activate the immune system in HIV-1 co-infected individuals and may lead to more rapid
HIV disease progression. This study will evaluate the potential impact of treating helminths
in HIV-1 seropositive individuals. Markers of disease progression and immune activation will
be assessed. We will also measure the amount of virus in genital secretions to determine if
treatment of co-infection can reduce the infectiousness of HIV in these individuals.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborators:
Kenya Medical Research Institute Kenyatta National Hospital University of Nairobi